SCHEMBL6846083

SCHEMBL6846083

N#Cc1cccc(-c2cccc3c2ccn3-c2cccnc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.46
CHRNA5 P30532 2/20 0.46
CHRNA4 P43681 2/20 0.46
CYP1A2 P05177 6/20 0.45
CYP3A4 P08684 6/20 0.45
HSD17B10 Q99714 6/20 0.45
CYP2C19 P33261 5/20 0.45
ALDH1A1 P00352 5/20 0.45
CLK4 Q9HAZ1 5/20 0.45
ALOX15 P16050 3/20 0.45
MAPK1 P28482 3/20 0.45
KCNA5 P22460 2/20 0.45
KCNH2 Q12809 2/20 0.45
NEK1 Q96PY6 1/20 0.44
CYP2D6 P10635 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
OXTR P30559 1/20 0.42
AVPR1A P37288 1/20 0.42
CYP11B2 P19099 4/20 0.41
CYP11B1 P15538 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6846105 0.83 MAPK14 (0.49) CHRNB2CHRNA5CHRNA4CYP1A2CYP3A4
SCHEMBL6847772 0.82 DYRK1A (0.47) CYP1A2CYP3A4HSD17B10ALDH1A1MAPK1
SCHEMBL6657600 0.82 CYP11B1 (0.43) CHRNB2CHRNA5CHRNA4CYP1A2CYP3A4
SCHEMBL6844276 0.81 CDC7 (0.44) CYP1A2ALDH1A1CYP11B2CYP11B1KDM4E
SCHEMBL6654549 0.80 CYP11B2 (0.53) CHRNB2CHRNA5CHRNA4CYP1A2CYP3A4
SCHEMBL6840695 0.79 NPY5R (0.44) KCNA5KCNH2KDM4E
SCHEMBL6846191 0.78 DHPS (0.50) CYP1A2CYP3A4ALDH1A1KCNA5KCNH2
SCHEMBL6665169 0.78 CYP17A1 (0.49) CYP1A2CYP11B2CYP11B1CYP17A1CYP19A1
SCHEMBL6657827 0.76 CYP17A1 (0.41) CYP1A2CYP3A4HSD17B10MAPK1CYP11B2
SCHEMBL6840527 0.76 S1PR1 (0.47) CYP1A2CYP3A4HSD17B10CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 CHRNB2 3541/4885CHRNA5 2650/4885CHRNA4 4040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.